Neurocrine Biosciences Inc. (NASDAQ:NBIX) is one of the 11 best debt-free stocks to invest in right now. Following a recent investor meeting with Neurocrine Biosciences’ senior leadership, Guggenheim analyst Yatin Suneja reaffirmed a Buy rating on the stock on June 4, keeping his price target steady at $165. The discussion covered several key areas of interest to investors, including commercial performance and future catalysts.
A scientist in a labcoat examining a vial of experimental biopharmaceuticals.
Management pointed to continued momentum in Ingrezza, with expectations for quarter-over-quarter sales growth in Q2 and a stronger performance in the second half of 2025. They also addressed investor concerns about potential pricing pressure on TEVA’s Austedo under the Inflation Reduction Act. While the IRA remains a point of uncertainty, the management is working toward equal access with TEVA.
The team also highlighted a significant population of untreated patients, underscoring long-term growth potential for VMAT2 inhibitors.
Neurocrine Biosciences Inc. is a leading neuroscience-focused biopharmaceutical company that discovers and develops treatments for patients with underserved neurological, neuroendocrine, and neuropsychiatric disorders.
READ NEXT: Harvard University Stock Portfolio: Top 10 Stock Picks and 20 Undervalued Momentum stocks that are Taking Off.
This article is originally published at Insider Monkey.
